Dulaglutide vs Gonadorelin
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
DulaglutideSexual Health & LibidoAnti-Aging & Longevity
Gonadorelin- Summary
- Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist approved by the FDA for type 2 diabetes management and cardiovascular risk reduction. It consists of two GLP-1 analog chains fused to a modified IgG4 Fc fragment, extending its half-life to approximately 5 days. While primarily a diabetes medication, it produces meaningful weight loss and has established cardiovascular outcomes data from the REWIND trial.
- Gonadorelin is the synthetic form of endogenous GnRH (gonadotropin-releasing hormone). It stimulates the pituitary to release LH and FSH, maintaining testicular function and testosterone production. Widely used alongside TRT to prevent testicular atrophy and preserve fertility.
- Half-Life
- ~5 days
- ~2–4 minutes (extremely short); pulsatile dosing required to avoid desensitization
- Admin Route
- SubQ
- SubQ, Intranasal
- Research
- —
- —
- Typical Dose
- 0.75 mg → 1.5 mg
- 100 mcg
- Frequency
- Once weekly
- Twice daily (every 12 hours)
- Key Benefits
- FDA-approved for type 2 diabetes
- Once-weekly subcutaneous dosing via auto-injector pen
- Reduces HbA1c by approximately 1.1–1.6%
- Modest weight loss of 1.5–3 kg at approved doses
- Demonstrated cardiovascular risk reduction (REWIND trial)
- Established long-term safety profile
- Renal protective effects in CKD
- Maintains testicular size during TRT
- Preserves fertility and sperm production during testosterone use
- Stimulates endogenous LH/FSH production
- Maintains HPG axis function during exogenous hormone use
- Used for HCG-free TRT protocols
- Helps restart natural testosterone production (PCT)
- Side Effects
- Nausea (most common, typically transient)
- Diarrhea
- Vomiting
- Decreased appetite
- +3 more
- Injection site reactions
- Headache
- Nausea at initiation
- Tachycardia (rare)
- +1 more
- Stacks With
- —
- —